Quantify

Biogen Inc. vs Pfizer, Inc. — Stock Comparison

Biogen Inc. (BIIB) and Pfizer, Inc. (PFE) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.

vs
Q·Score Winner
Biogen Inc.
BIIB7.5/10vs 6.2/10

Biogen Inc. scores ahead of Pfizer, Inc. on Q·Score (7.5 vs 6.2 out of 10), led by Growth (7.8 vs 5.1) and Health (9.7 vs 7). Pfizer, Inc. scores higher on Valuation, reflecting stronger P/E and price-target positioning. Analyst price targets imply similar upside for both: +10.3% for BIIB and +11.4% for PFE.

Price Performance

Normalised to 100 at period start — shows relative performance.

Loading…
● BIIB● PFE

Q·Score Breakdown

7.5
Bullish
Overall
6.2
Neutral
7
Quality
6.4
9.7
Health
7
7.8
Growth
5.1
6.4
Valuation
7
6.7
Sentiment
5.3
BIIB

Clean balance sheet with low leverage (0.4× debt-to-equity).

PFE

Consistently beats earnings estimates (4/4 quarters).

⚠ earnings contracting 10% year-over-year.

Analyst Consensus

Bullish
+10.3%
Target $220.63
30 analysts
Neutral
+11.4%
Target $29.19
27 analysts

Fundamentals

BIIB
PFE
21.5×
Trailing P/E
20.0×
12.0×
Forward P/E
9.3×
13.80%
Profit Margin
11.83%
78.72%
Gross Margin
74.80%
7.70%
ROE
8.31%
1.90%
Revenue Growth
5.40%
31.10%
Earnings Growth
-10.10%
0.18
Beta
0.29
—
Dividend Yield
6.56%
$29.5B
Market Cap
$149.4B
52-Week Range
BIIB
$12193% of range$206
PFE
$2355% of range$29

Frequently Asked Questions

BIIB vs PFE: which stock scores better overall?

Based on Q·Score, Biogen Inc. (BIIB) scores 7.5/10 versus Pfizer, Inc. (PFE) at 6.2/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.

Which has better revenue growth: BIIB or PFE?

Biogen Inc. (BIIB) scores higher on Growth (7.8/10 vs 5.1/10). Biogen Inc. reports revenue growth (1.9% YoY) while Pfizer, Inc. reports (5.4% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.

Is BIIB or PFE more attractively valued?

Pfizer, Inc. (PFE) scores higher on Valuation (7/10 vs 6.4/10). BIIB trades at 12.0× P/E versus PFE at 9.3×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.

What do analysts say about BIIB vs PFE?

There are 30 analysts covering BIIB with a consensus price target of $220.63, and 27 analysts covering PFE with a consensus target of $29.19. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.

Which is more profitable: BIIB or PFE?

Biogen Inc. (BIIB) scores higher on Quality (7/10 vs 6.4/10). Net profit margin: BIIB at 13.8%, PFE at 11.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.

Which has stronger financial health: BIIB or PFE?

Biogen Inc. (BIIB) scores higher on Financial Health (9.7/10 vs 7/10). Market beta: BIIB at 0.18, PFE at 0.29. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.

What are the market caps of BIIB and PFE?

Biogen Inc. (BIIB) has a market capitalisation of $29.5B, while Pfizer, Inc. (PFE) has a market cap of $149.4B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.

Do BIIB or PFE pay dividends?

BIIB does not currently pay a dividend, while PFE pays a dividend yield of 6.56%. Dividend yields fluctuate with share price and company payout decisions.

Related Comparisons

JNJ vs PFEMRNA vs PFELLY vs PFEBIIB vs VRTXBIIB vs REGN

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →

Data provided by Yahoo Finance ·  Updated on each page load ·  For informational purposes only · Not financial advice · Quantify.biz © 2026